Pharma’s Virus Response May Impact Trump’s Drug Pricing Plans

The pharmaceutical industry’s push to combat the spreading coronavirus could deter the implementation of some drug- pricing policies from both the White House and Congress, according to Height Capital Markets.

As companies ramp up developments for therapies and express optimism on their potential success, their partnership with President Trump could push him to “change the existing, negative narrative and deter serious drug-pricing actions,” analysts led by Hunter Hammond said in a note.